Comparative effectiveness of rivaroxaban and warfarin for stroke prevention in multi-morbid patients with nonvalvular atrial fibrillation

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/36744
• EU PAS number:
  EUPAS21800
• Study ID:
  36744
• Official title and acronym:
  Comparative effectiveness of rivaroxaban and warfarin for stroke prevention in multi-morbid patients with nonvalvular atrial fibrillation
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study status:
  Finalised

Research institution and networks

Institutions

Bayer AG

Study timelines

Date when funding contract was signed

Planned: 02/11/2017

Actual: 02/11/2017

Study start date

Planned: 01/12/2017

Actual: 01/12/2017

Date of final study report

Planned: 30/10/2020

Actual: 07/07/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Study protocol

Initial protocol

19859_CSP_V2.0_2019-01-31_redacted

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable